Valsartan Lawsuit

Leads For Law Firms

Personal injury law firms are actively investigating claims on behalf of patients who took blood pressure medications containing valsartan and were later diagnosed with liver damage, tumors, or cancer. Patients who received blood pressure medication containing Valsartan may have legal recourse against the drug manufacturer and will be needing legal representation.

Law firms can connect with victims of Valsartan injuries by contacting Broughton Partners, a case generation and legal marketing firm that wants to help attorneys find only quality Valsartan qualified retainers. Patients who have suffered harmful side effects after taking Valsartan will be looking for a drug injury law firm for legal assistance. Broughton Partners connects personal injury law firms with Valsartan lawsuit leads and other drug injury leads. The Valsartan leads your law firm receives are qualified retainers who have been fully examined. Law firms looking for more Valsartan lawsuit leads can work with Broughton Partners and start receiving Valsartan lawsuit leads that fit their specific case criteria.

What is Valsartan?

Valsartan is an active ingredient in many generic drugs, including drugs used to treat hypertension, heart failure, left ventricular heart failure, and left ventricular heart dysfunction following myocardial infarction.

Valsartan is also prescribed in conjunction with hydrochlorothiazide (HCTZ) to treat hypertension.

Valsartan Linked to Serious Side Effects

Contaminated Valsartan Batches

Many valsartan recalls have been announced by the FDA to date, impacting batches sold by many pharmaceutical companies or re-packagers, including:

  • Major Pharmaceuticals
  • Actavis
  • Teva Pharmaceuticals
  • Solco Healthcare
  • A-S Medication Solutions LLC
  • AvKARE
  • RemedyRepack
  • Bryant Ranch Prepack Inc.
  • J. Harkins Company, Inc.
  • Lake Erie Medical, Doing Business As Quality Care Products LLC
  • NuCare Pharmaceuticals
  • Proficient Rx

NDMA Exposure

Short-term exposure to NDMA can cause liver damage, whereas long-term exposure may also reduce platelet counts in the blood. Long-term ingestion of NDMA may lead to an increased occurrence of tumors in the liver, kidneys or lungs

Valsartan Lawsuit Claims

  • The pharmaceutical company developed and sold harmful medications.
  • The pharmaceutical company failed to properly warn patients and doctors of Valsartan’s severe side effects.
  • Plaintiffs suffered from severe side effects as a result of taking Valsartan.

Valsartan Lawsuit

There have been a series of recalls involving several well-known high blood pressure medications. Some of these medications, offered by different manufacturers include Losartan, Valsartan, and Irbesartan. A massive recall came from Aurobindo Pharma USA, who voluntarily recalled over 80 lots of their popular high blood pressure medications, including the following:

  • Valsartan HCTZ Tablets
  • Amlodipine Valsartan Tablets USP
  • Valsartan Tablets USP

Nearly 80 million high blood pressure prescriptions have been written since 2016. Beyond that, many people who have come to rely on these medications are now left scrambling to find alternatives.

Patients are now filing lawsuits against the manufacturers of Valsartan alleging that many batches of the drug from 2012 to 2018 were contaminated with N-nitrosodimethylamine (NDMA), a probable carcinogen.

Valsartan lawsuits are based on the following criteria:

  • The plaintiff used Valsartan for at least one year in 2014 or later
  • After at least one year of taking Valsartan, the plaintiff was diagnosed with:
    • Liver Cancer
    • Kidney Cancer
    • Stomach Cancer
    • Intestinal Cancer
    • Colon and Rectal Cancer

Lawsuits are starting to be filed in qualified retainers relating to the heart drug Valsartan. The drug recall was announced about a year ago and new carcinogens are still being discovered in this class of medications. Around the first 50 of these lawsuits have been consolidated into multi-district litigation in federal court in New Jersey. The full impact that drugs like Valsartan had on patients has yet to be determined. Although only a handful of lawsuits have been filed so far, it is anticipated that several thousand lawsuits will eventually be filed as patients begin to realize the extent of the harm they have suffered from taking these medications. There are several different drugs in the class and each has been found to have been tainted. This will further expand the pool of lawsuits. The relevant lawsuits recently achieved multi-district status in February 2019 so these qualified retainers are still in the development phase. There is not yet any discovery scheduled and any bellwether qualified retainers are still far in the future. It is likely that the scope of these lawsuits may change as more is revealed about the character and extent of the contaminants impacting the medications.

May 2018

The European Medicines Agency (EMA) reviews medications containing Valsartan that were supplied by Zhejiang Huahai Pharmaceuticals. The EMA’s review started after the company detected NDMA in the medication it was supplying to European Union manufacturers.

July 2018

The FDA announces that 3 manufacturers will be voluntarily recalling their dangerous drugs that contain Valsartan. The FDA also provides regulations and guidance on how to properly test Valsartan for any contamination.

August 2018

Torrent Pharmaceuticals recalls 14 lots of Valsartan/Amlodipine/HCTZ tablets due to NDMA contamination.

August 2018

Camber Pharmaceuticals recalls specific batches of Valsartan contaminated with NDMA.

November 2018

Various lots of Valsartan are recalled due to contamination with NDMA, NDEA, and/or NMBA. Teva Pharmaceuticals removes all amlodipine/valsartan combination tablets and amlodipine/valsartan/hydrochlorothiazide combination tablets after NDEA  contamination was found.

February 2019

Valsartan lawsuits were consolidated into a multi-district litigation (MDL) in the District of New Jersey.

References

Charles Patrick Davis, MD, PhD. “Diovan”, RxList. Accessed May 31, 2019.

WebMD. “Valsartan”, WebMD. Accessed May 31, 2019.

Mayo Clinic. “Valsartan (Oral Route)”, Mayo Clinic. Accessed May 31, 2019.

Jacqueline Howard. “Valsartan recall: 4 things patients should know”, CNN. Accessed May 31, 2019.

Memorial Sloan Kettering Cancer Center. “Valsartan and Hydrochlorothiazide”, Wolters Kluwer Clinical Drug Information, Inc. Accessed May 31, 2019.

Megan Trimble. “Blood Pressure Medicine Recalled Over Cancer Concern”, U.S. News. Accessed May 31, 2019.

Menu